The European Patent Office (EPO) has published patent application EP4494637A1, filed by Kaneka Corporation, detailing a solid composition containing a specific crystal form (Form II) of reduced Coenzyme Q10. The patent, with a publication date of March 18, 2026, covers aspects related to Coenzyme Q10's use in pharmaceutical and food applications, including its potential health benefits such as improving circulation and antioxidant properties.

This publication represents a new intellectual property filing. For companies in the pharmaceutical and food sectors, particularly those involved with Coenzyme Q10 or similar compounds, this patent may impact product development, formulation strategies, and market exclusivity. While patents do not impose direct compliance obligations, they are critical for understanding the competitive landscape and potential licensing requirements.